Compare RTX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | NVO |
|---|---|---|
| Founded | 1934 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.1B | 269.6B |
| IPO Year | 1994 | N/A |
| Metric | RTX | NVO |
|---|---|---|
| Price | $209.22 | $38.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 11 |
| Target Price | ★ $190.69 | $51.00 |
| AVG Volume (30 Days) | 6.0M | ★ 21.6M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | 1.33% | ★ 3.15% |
| EPS Growth | ★ 39.72 | N/A |
| EPS | ★ 4.96 | N/A |
| Revenue | ★ $80,738,000,000.00 | N/A |
| Revenue This Year | $6.42 | N/A |
| Revenue Next Year | $6.66 | $4.39 |
| P/E Ratio | $41.12 | ★ $13.60 |
| Revenue Growth | ★ 17.15 | N/A |
| 52 Week Low | $112.27 | $35.85 |
| 52 Week High | $214.50 | $82.23 |
| Indicator | RTX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 31.52 |
| Support Level | $193.07 | N/A |
| Resistance Level | N/A | $50.30 |
| Average True Range (ATR) | 5.45 | 0.89 |
| MACD | 0.32 | -0.21 |
| Stochastic Oscillator | 75.69 | 19.46 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.